Dataset from Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC)

CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational
integrin inhibitor, cilengitide, in combination with standard treatment versus standard
treatment alone in newly diagnosed glioblastoma subjects with a methylated
O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor
tissue.

The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling
element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be
a predictive marker for benefit from temozolomide (TMZ) treatment.